Cutaneous Adverse Events in Patients with Chronic Hepatitis C during Treatment with Directly Acting Antiviral Agents: A cohort study

The study investigated the dermatological side effects of direct-acting antiviral (DAA) therapy in 140 HCV-positive patients in Egypt, treated with sofosbuvir and daclatasvir, with or without ribavirin. Over 12 weeks, 34% of patients experienced skin-related adverse reactions, including itching, drug eruptions, hyperpigmentation, dry mouth, acne, telogen effluvium, and ecchymosis. These effects were mostly reversible and did not necessitate stopping the treatment.